Results
1 -
10 of
14Bowles Paul, Brenek Steven, Caron Stephane, Do Nga, Drexler Michele T, Duan Shengquan, Dubé Pascal, Hansen Eric C., Jones Brian P, Jones Kris Nicole, Ljubicic Tomislav A, Makowski Teresa, Mustakis Jason, Nelson Jade D., Olivier Mark, Peng Zhihui, Perfect Hahdi, Place David W, Ragan John A., Salisbury John J, Stanchina Corey L, Vanderplas Brian C, Webster Mark Eric, Weekly Rodney Matthew.
Commercial Route Research & Development for SGLT2 Inhibitor Candidate Ertugliflozin, Organic Process Research & Development, 2013 Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes, Synthesis of Heterocycles in Contemporary Medicinal Chemistry Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes, Clinical Pharmacokinetics Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials, Acta Diabetologica Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study, Diabetes Therapy Ertugliflozin: First Global Approval, Drugs Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study, Diabetes Therapy Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study, Diabetes Therapy Fixkombination von DPP4- und SGLT-2-Hemmer, MMW - Fortschritte der Medizin